August 27, 2021 -- Insilico Medicine is collaborating with 4B Technologies to develop small-molecule therapies for amyotrophic lateral sclerosis (ALS) and other major neurological diseases.
The companies said the collaboration will leverage Insilico's synthetic biology and synthetic chemistry artificial intelligence platform and 4B Technologies' insights in targeting strategies, biology, translational research, and clinical medicine in the field of neurological diseases.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
